AMGN logo Amgen +
Amgen
+

Amgen Overview

Company: Amgen
CEO: Robert A. Bradway
Founded: Apr 8, 1980
Symbol: AMGN
Exchange: NASDAQ
Industry: Drug Manufacturers - General
Sector: Healthcare
About

Amgen, established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories,luding inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable exampleslude Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering theidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers,luding physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics and Plexium

Continue reading...

Amgen (AMGN)

  • Stock Price
  • Volume
360.45 +115.75 +47.30%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Amgen annual revenue was $36.75 B in 2025.

Net Income

Amgen annual net income was $7.71 B in 2025.

Employees

Amgen annual employee count was 31,500 in 2025.

Revenue by Segment

Amgen’s revenue by segment: Aranesp: $1.39 B, BLINCYTO: $1.56 B, ENBREL: $2.23 B, EVENITY: $2.10 B, KRYSTEXXA: $1.34 B, Nplate: $1.52 B, Otezla: $2.27 B, Other Products: $7.26 B, Product and Service, Other: $1.60 B, Prolia: $4.41 B, Repatha: $3.02 B, TEPEZZA: $1.90 B, TEZSPIRE: $1.48 B, Vectibix: $1.18 B and XGEVA: $2.08 B in 2025.

Revenue by Region

Amgen’s revenue by region: Non-US: $10.33 B and UNITED STATES: $26.42 B in 2025.

Executive Salary

Robert A. Bradway Chief Executive Officer and President, at Amgen, m...

Revenue per Employee

Amgen revenue per employee was $1.17 M in 2025.

Profit per Employee

Amgen profit per employee was $244.79 K in 2025.

Income Statement

Operating Income

Amgen annual operating income was $14.89 B in 2025.

Research & Development

Amgen annual research & development expense was $7.27 B in 2025.

Tax Rate (%)

Amgen annual Tax Rate was 14.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Amgen annual total assets was $90.59 B in 2025.

Total Liabilities

Amgen annual total liabilities was $81.93 B in 2025.

Capital Expenditure

Amgen annual capital expenditures was -$1.86 B in 2025.

Ratios

Return on Equity (ROE)

Amgen annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Amgen annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Amgen annual debt to equity was 630.68% in 2025.

Profitability

Gross Profit Margin (%)

Amgen annual gross profit margin was 82.52% in 2025.

Operating Income Margin (%)

Amgen annual operating income margin was 40.52% in 2025.

Net Income Margin (%)

Amgen annual net income margin was 20.99% in 2025.

Earning Per Share

Amgen annual earning per share was $14.33 in 2025.

EBITDA

Amgen annual EBITDA was $17.13 B in 2025.

Free Cash Flow (FCF)

Amgen annual free cash flow(FCF) was $8.10 B in 2025.

Valuation

Enterprise value

Amgen annual enterprise value was - in 2025.

Enterprise value to Revenue

Amgen annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Amgen annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was Amgen founded?

Amgen was founded on Apr 8, 1980, which makes the company 46 years old.

Sign up for free to view

Who is the CEO of Amgen?

Robert A. Bradway is the CEO of Amgen.

What industry and sector is Amgen in?

Amgen operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are Amgen's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000318154
  • SIC (Standard Industrial Classification): 2836
  • ISIN (International Securities Identification Number): US0311621009

Sign up for free to view

How many employees does Amgen have?

Amgen has 31,500 employees.

What is the revenue of Amgen?

In fiscal year 2025, Amgen generated a revenue of $36.75 Billion.

What is the net income of Amgen?

In fiscal year 2025, Amgen reported a net income of $7.71 Billion.

What is Amgen's biggest product segment?

Other Products is Amgen's biggest product segment, representing 20.55% of its total revenue.

When was Amgen listed on the stock exchange?

Amgen went public on Jun 17, 1983, through its Initial Public Offering (IPO), and it has been 43 years since then.

Sign up for free to view

What is the ticker symbol of Amgen, and where is it listed?

Amgen's ticker symbol is AMGN, and the company is listed on the NASDAQ stock market exchange.

What is Amgen's current stock price?

Amgen's current stock price is $360.52 as of Jul 14, 2026.

What is Amgen's market capitalization?

As of , Amgen's market cap is .

What is Amgen's ranking in the world?

Ranked #8among 2,804 companies based on market cap.

Who are the top competitors of Amgen?

Competitors of Amgen include Eli Lilly and Company, Johnson & Johnson and AbbVie, and more.

People Also Search For

Submit feedback to Bullfincher